ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / JUNS / insiders
EOCN (34) CMND (47) MBIO (41) ERNA (33) ⌘ Pro Terminal β†’

Jupiter Neurosciences Inc. (JUNS) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$2.31 +12.68% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.36

Jupiter Neurosciences Inc. (JUNS) carries a Roarable Rating of E (Strong Sell) with 29/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E β€’ RED ALERT Cap $3.0M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on JUNS Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is JUNS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, Jupiter Neurosciences Inc. (NASDAQ: JUNS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $2.31 (+12.68% 1D, market cap $3.0M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, JUNS ranks #850 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does JUNS compare to EOCN and CMND in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), JUNS carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of 80.6%, and ROIC of -35.0%. By comparison, EOCN (Eocene Ltd.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $3.0M) and CMND (Clearmind Medicine Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC β€”, cap $3.1M). Among the 5-stock peer group, JUNS leads on earnings multiple (N/A) while JUNS leads on capital efficiency (-35.0% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for JUNS?
β–Ό

Per JUNS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001679628), Jupiter Neurosciences Inc. generated $21.8K in revenue (-99.7% YoY), -$8.6M in net income, and -$5.4M in free cash flow against $5.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $2.36 (+2.09%)🧬 Dilution Drag (+1.28% YoY Shares)βš™οΈ Cash Engine: 8/20 (D-) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (29/100 Β· E) historically underperformed SPY in 71% of rolling 90-day windows (-9.8% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ E
025507510029
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E Β· Rk D-
Cash (8)Whales (3)SEC (8)Macro (7)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-13% Base Target
$109 Bull$2 Base$2 Bear
πŸ“¬ FREE JUNS RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for JUNS)Realized 20D OHLCV Swing Band: Β±12.5%
Deterministic 5-Pillar Attribution (29/100 Composite)
πŸ” WHY JUNS SCORES 29/100 (E) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: Cash Engine Quality+8/20 pts (28% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 1.8% Gross Margin

β–² #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (28% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 2/9

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
37
Grade E$3.19-12.9% Next Q
Q2 (-2Q)
34
Grade E$2.78-10.1% Next Q
Q3 (-1Q)
32
Grade E$2.50-7.6% Next Q
Current
29
Grade E$2.31-9.8% Hist 90D Ξ±
Trajectory: E (37) β†’ E (29)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a JUNS Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While JUNS currently carries a cautious 29/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.96) and Max Pain ($2.43) forces dealer call-delta covering toward $108.68.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $JUNSβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œJUNS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 29%NO 71%Trade / Inspect Odds β†’
SEC FORM 4 Γ— 13F HEDGE FUNDS Γ— CONGRESSIONAL STOCK ACT

JUNS Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales β†’
β–² Disclosed Buys: 0 ($0)β–Ό Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (JUNS)

No recent open-market Form 4 cluster sales or emergency dumps flagged on JUNS. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring JUNS)

  • βœ“Walkthrough of JUNS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
JUNS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -91.47%β–² RESISTANCE BREAKOUT
2026-11-04O $2.05H $2.31L $2.05C $2.31VOL 31.8K
RES: $0.08SUP: $1.99SMA50: $2.96SMA200: $19.61
$82.19$60.47$38.75$17.03$-4.69RES $0.08SUP $1.99$2.312026-05-052026-06-182026-08-052026-09-212026-11-04
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

JUNS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ JUNS Butterfly Map β†’ + Track JUNS β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -99.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on JUNS today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for JUNS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for JUNS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (JUNS)

Health Care Rank #850 of 1015 βš”οΈ EOCN vs JUNS Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (JUNS vs. EOCN, CMND, MBIO, ERNA)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Jupiter Neurosciences Inc. (JUNS) ranks #850 by composite RQD confidence (29/100, grade E) and #975 by equity capitalization ($3.0M). Within this direct 5-issuer industry benchmark cohort, JUNS leads on earnings valuation at N/A trailing P/E, while JUNS leads on capital efficiency and profitability with -35.0% ROIC and 80.6% gross margin. CMND currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with JUNS at 29/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
JUNS ACTIVE
Jupiter Neurosciences Inc.
E 29/100 β€” 80.6% -35.0% +12.68% $3.0M Benchmark Subject
EOCN
Eocene Ltd.
E 34/100 β€” β€” -35.0% -7.54% $3.0M /eocn-vs-juns β†’
CMND
Clearmind Medicine Inc.
D 47/100 β€” β€” β€” -1.27% $3.1M /cmnd-vs-juns β†’
MBIO
Mustang Bio Inc.
D- 41/100 β€” β€” -35.0% +3.72% $3.1M /mbio-vs-juns β†’
ERNA
Ernexa Therapeutics Inc.
E 33/100 β€” β€” -35.0% -1.01% $3.2M /erna-vs-juns β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001679628 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Jupiter Neurosciences Inc. (JUNS) reported GAAP revenue of $21.8K (-99.7% vs. FY2024 revenue of $8.7M , and -99.8% cumulative change since FY2023) , GAAP net income of -$8.6M, operating cash flow of -$5.4M, and free cash flow of -$5.4M (-38.4% YoY). On the balance sheet, JUNS closed FY2025 with $5.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $21.8K -$8.6M -$5.4M -$5.4M $5.6M β€”
FY2024 (FY) 2024-12-31 $8.7M -$2.4M -$3.9M -$3.9M $6.2M β€”
FY2023 (FY) 2023-12-31 $10.8M -$4.8M -$481.0K -$481.0K β€” β€”

3. JUNS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is JUNS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Jupiter Neurosciences Inc. (NASDAQ: JUNS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $2.31 (+12.68% 1D, market cap $3.0M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, JUNS ranks #850 in composite RQD confidence.

How does JUNS compare to EOCN and CMND in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), JUNS carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of 80.6%, and ROIC of -35.0%. By comparison, EOCN (Eocene Ltd.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $3.0M) and CMND (Clearmind Medicine Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC β€”, cap $3.1M). Among the 5-stock peer group, JUNS leads on earnings multiple (N/A) while JUNS leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for JUNS?

Per JUNS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001679628), Jupiter Neurosciences Inc. generated $21.8K in revenue (-99.7% YoY), -$8.6M in net income, and -$5.4M in free cash flow against $5.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is JUNS trading relative to its 50-day, 200-day, and 52-week technical levels?

JUNS last traded at $2.31 (+12.68% on volume of 31,804 shares), positioning the stock -21.96% below its 50-day simple moving average ($2.96) and -88.22% below its 200-day simple moving average ($19.61). Across its 52-week range of $2.05 to $103.50, JUNS sits at the 0.3% percentile with a 14-day RSI of 41.5 (NEUTRAL RANGE) and an implied next-earnings move of Β±12.5% ($2.02 to $2.60).

Direct Sub-Reports: JUNS RQD Cockpit JUNS 12M Forecast JUNS Earnings & Move JUNS Dividends & DRIP JUNS Insiders & 13F JUNS Whale Options JUNS Profit Sankey JUNS News & Why
ROARABLE RATING BRIEF β€’ RQD 29/100 (E) βœ“ SEC XBRL & RQD VERIFIED

JUNS β€” Jupiter Neurosciences Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Jupiter Neurosciences Inc. (JUNS) earns a live Roarable RQD composite score of 29/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $2.31 (+12.68% 1D, market capitalization $3.0M).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 80.6%, operating margin of -60.0%, and free cash flow yield of β€”.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Jupiter Neurosciences Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Per the recent news and catalysts section, the company announced the first patient dosed in a Phase 2a RESET Trial in Parkinson's disease and the exploration of strategic options to maximize shareholder value.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Jupiter Neurosciences Inc. (JUNS) reported $21.8K in annual revenue (up from $8.7M in FY2024, -99.7% YoY) and -$8.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($10.8M revenue, -$4.8M net income) through FY2025, JUNS scaled operating cash flow to -$5.4M and free cash flow to -$5.4M, backed by $5.6M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (E β€’ RQD 29/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of β€” and institutional whale pillar of 3/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $2.05 – $103.50 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The supply chain is NONE, with an empty list of butterfly links and an empty list of proprietary signals. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are therefore β€” The only sector context provided is the Health Care sector and Biotechnology: Pharmaceutical Preparations industry classification, and the beta of 1.0 in the market data. A prospective investor should note that the absence of mapped dependencies means the source data cannot identify which suppliers, partners, or customers would transmit a shock to the company.

  • Key Question #1: Can JUNS sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $21.8K and free cash flow of -$5.4M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is JUNS's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

JUNS Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Jupiter Neurosciences Inc. (JUNS) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to JUNS Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

JUNS Bull vs. Bear Conversation Board β€” What's Your Call at $2.31?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON JUNS 🐻 33% BEARISH CONVICTION
1. Pick Your Side on JUNS:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
QU QuantViper RQD DEBATE OPENER β€’ Systematic Momentum Desk πŸ‚ BULLISH 🎯 Target: $2.38 (+16.1%)
πŸ“Œ Pinned Debate

The company has begun dosing its first patient in a Phase 2a RESET Trial in Parkinson's disease and is exploring strategic options to m

Picked up a starter position in JUNS in my $100K Virtual Cash book at $2.05. The company has begun dosing its first patient in a Phase 2a RESET Trial in Parkinson's disease and is exploring strategic options to maximize shareholder value.. Trading inside a $2.05–$105.00 52-week range with 0.0% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.

SectorRotator πŸ‚ BULL

@QuantViper Agree on the RQD 29/100 quality, though with 1.0 beta I'm scaling in with half-size at $2.05 and keeping dry powder in case we test $1.91.

SH ShortSeller_Dan RQD DEBATE OPENER β€’ Forensic Short Bias 🐻 BEARISH 🎯 Target: $1.64 (-20.0%)
Spot @ $2.05

The company reported no revenue in any of the three most recent fiscal years, with FY 2025 net income of -$8.6M and an FCF yield of 0%.

The company reported no revenue in any of the three most recent fiscal years, with FY 2025 net income of -$8.6M and an FCF yield of 0%.. Look at the math on JUNS: paying current EV/EBITDA multiples for -35.0% ROIC and -60.0% operating margins leaves zero margin of safety if Biotechnology: Pharmaceutical Preparations demand softens. I'd wait for a retest of $1.80 before getting long.

LIVE TAPE